This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heartfailure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with HeartFailure with Preserved Ejection Fraction (HFpEF).
Bayers FINEARTS-HF study revealed that finerenone could be poised to become the next big heartfailure treatment at ESC 2024, and a new series of JACC sub-studies just further strengthened its case. Finerenone (Bayers Kerendia) got its start with CKD, and is the first mineralocorticoid receptor antagonist to be used for HF.
Abstract Background N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are lower in patients with obesity. The interaction between body mass index (BMI) and NT-proBNP with respect to heartfailure (HF) risk remains incompletely defined. pg/mL lower NT-proBNP per 1 kg/m 2 higher BMI; p<0.001).
Previous studies have associated obesity with negative changes in the right ventricle using imaging techniques. However, the connection between obesity and more direct measures of right ventricle function, particularly those reflecting hemodynamic consequences, have been unclear. Original article: Circ Heart Fail.
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heartfailure (HF) with preserved ejection fraction (HFpEF). Echocardiography demonstrated increased CO with obesity, but not estimated right atrial (RA) pressure or E/e′. Overall, 60.9%
Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation. Current consensus age- and BMI-stratified rule-in thresholds demonstrated only 65% specificity (95% CI, 57%72%). Circulation, Ahead of Print.
Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.
Background: Patients with heartfailure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heartfailure. n=393) were female; BMI 38.26.7kg/m2, KCCQ-CSS 53.518.5, n=393) were female; BMI 38.26.7kg/m2, KCCQ-CSS 53.518.5,
Notably, MAG showed superior survival for patients with a BMI less than 40, whereas patients with a BMI of 40 or higher had superior survival with SAG. Survival outcomes were equivalent between MAG and SAG for patients aged 80 years or older, and those with severe heartfailure , renal failure, peripheral vascular disease, or obesity.
Association between epicardial adipose tissue (EAT) and cardiac dysfunction in severe obesity. BMI, body mass index; GLS, global longitudinal strain; LASct, left atrial contractile strain. Abstract Aim Epicardial adipose tissue (EAT) plays a role in obesity-related heartfailure with preserved ejection fraction.
Background:Patients with heartfailure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 mg or placebo for 52 weeks. across domains;P<0.05
For adults with overweight and obesity, resistance exercise increases lean body mass and reduces body fat percentage and fat mass — improving overall body composition. Of course, these benefits can also extend to individuals with a BMI in the normal range.
For adults with overweight and obesity, resistance exercise increases lean body mass and reduces body fat percentage and fat mass — improving overall body composition. Of course, these benefits can also extend to individuals with a BMI in the normal range.
Prognostic value of several alternative anthropometric measures in patients with non-ischaemic heartfailure with reduced ejection fraction. The lower part of the figure shows the risk of mortality according to continuous body mass index (BMI) ( left panel ) and waist-to-height ratio (WHtR) ( right panel ).
Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heartfailure that has had few therapeutic options. The study analyzed the effects of semaglutide 2.4
Objective While greater body mass index (BMI) is associated with increased risk of developing atrial fibrillation (AF), the impact of BMI on outcomes in newly diagnosed AF is unclear. The study population comprised 40 482 participants: 703 underweight (BMI <18.5 kg/m 2 ), 13 095 normal (BMI=18.5–24.9
A multivariate logistic regression model was used to assess for statistically significant differences after controlling for potentially confounding variables including age, sex, BMI, AF, prior MI, COPD, DM, HTN, serum creatinine, and NYHA functional class.Results:A total of 320 patients were included in this analysis, with 230 on BB (72%).
Abstract Aims Understanding the global burden of disease attributable to high body mass index (BMI) is essential for informing public health strategies and interventions to mitigate the impact of obesity-related conditions. Globally in 2021, the deaths and DALYs attributable to high BMI have risen 2.54-fold fold and 2.68-fold
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content